Cancer Causes & Control

, Volume 5, Issue 3, pp 249–254 | Cite as

Difficulty in eradicatingHelicobacter pylori in a population at high risk for stomach cancer in Venezuela

  • Eva Buiatti
  • Nubia Muñoz
  • Jorge Vivas
  • Elsa Cano
  • Simon Peraza
  • Elsa Carillo
  • Denis Castro
  • Victor Sanchez
  • Olga Andrade
  • Maja Benz
  • Silvia de Sanjosé
  • Walter Oliver
Research Papers

Abstract

The bacteriumHelicobacter pylori (HP) has been implicated in the etiology of precancerous lesions of the stomach and there is evidence suggesting that it may influence the efficacy of chemoprevention of gastric cancer with vitamin C. Eradication seldom has been attempted in populations from developing countries, with a high prevalence of HP frequently resistant to metronidazole. A randomized, double-blind, controlled trial to evaluate the efficacy of colloidal bismuth subcitrate (120 mg q.i.d.) and amoxycillin (500 mg q.i.d.) in eradicating HP was conducted in 220 subjects drawn from a population with a high prevalence of metronidazole-resistant HP in Tachira state, Venezuela. One month after completion of two weeks' treatment, eradication rates of 6.5 percent in the treatment group and two percent in the placebo group were estimated on the basis of HP diagnosis in biopsies, and of 13.9 percent compared with 3.9 percent on the basis of a14C-urea breath test, although the negative predictive value of the breath test was very low compared with HP diagnosis in biopsies. In the treatment group, particularly among males, a significant decrease in bacterial load was detected. Reasons for failure of treatment in high HP-prevalence areas are discussed, and it is suggested that primary prevention of HP infection may be the optimal approach to reducing levels of stomach cancer in these high-risk groups.

Key words

Amoxycillin bismuth eradication Helicobacter pylori stomach cancer Venezuela 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Forman D, Newell DG, Fullerton F, et al. Association between infection withHelicobacter pylori and risk of gastric cancer; evidence from a prospective investigation.Br Med J 1991;302:1302–5.Google Scholar
  2. 2.
    Parsonnet J, Friedman GD, Vandersteen DP, et al.Helicobacter pylori infection and the risk of gastric carcinoma.N Engl J Med 1991;325:1127–31.PubMedGoogle Scholar
  3. 3.
    Nomura A, Stemmerman GN, Chyou PH, Kato I, Perez-Perez I, Blaser MJ.Helicobacter pylori infection and gastric carcinoma among. Japanese Americans in Hawaii.N Engl J Med 1991;325:1132–6.PubMedGoogle Scholar
  4. 4.
    Mégraud F. Epidemiology ofHelicobacter pylori infection.Gastroenterol Clin North Am 1993;22:73–88.PubMedGoogle Scholar
  5. 5.
    Sobala GM, Grabtree J, Dixon MF, et al. AcuteHelicobacter pylori infection: clinical features, local and systemic immune response, gastric mucosal histology and gastric juice ascorbic acid concentrations.Gut 1991;32: 1415–8.PubMedGoogle Scholar
  6. 6.
    Axon ATR.Campylobacter pylori—therapy review.Scand J Gastroenterol 1989a;24:35–8.Google Scholar
  7. 7.
    Axon ATR.Helicobacter pylori therapy—effect of peptic ulcer disease.J Gastroenterol Hepatol 1989b;6: 131–7.Google Scholar
  8. 8.
    Peraza S, Castro D, Oliver WE, et al. Investigation histologica deHelicobacter pylori en 265 biopsias gastricas consecutivas.GEN 1991;45:163–6.Google Scholar
  9. 9.
    Muñoz N, Oliver W, Sobala GM, et al. Prevalence ofHelicobacter pylori infection and effect of antioxidants in a high risk population for gastric cancer in Venezuela.Ital J Gastroenterol 1991;23 (9, suppl. 2):15.PubMedGoogle Scholar
  10. 10.
    Marshall BJ, Plankey MW, Hoffman SR, et al. A 20-minute breath test forHelicobacter pylori.Am J Gastroenterol 1991;86:438–45.PubMedGoogle Scholar
  11. 11.
    SAS Institute Inc.SAS/STAT User's Guide, Version 6, Fourth Edition. Cary, NC, USA: SAS Institute, Inc., 1989.Google Scholar
  12. 12.
    Chiba N, Rao BV, Rademaker JW, Hunt RH. Meta-analysis ofHelicobacter pylori eradication trials (Abstract).Gastroenterol 1991;100 (Suppl. 5):A43.Google Scholar
  13. 13.
    Parsonnet J. Potential utility ofH. pylori screening and treatment in prevention of gastric cancer (Abstract).Irish J Med Sci 1992;161 (Suppl. 10):25.Google Scholar

Copyright information

© Rapid Communications of Oxford Ltd 1994

Authors and Affiliations

  • Eva Buiatti
    • 1
  • Nubia Muñoz
    • 2
  • Jorge Vivas
    • 3
  • Elsa Cano
    • 3
  • Simon Peraza
    • 3
  • Elsa Carillo
    • 3
  • Denis Castro
    • 3
  • Victor Sanchez
    • 3
  • Olga Andrade
    • 3
  • Maja Benz
    • 2
  • Silvia de Sanjosé
    • 2
  • Walter Oliver
    • 3
  1. 1.the Centro per lo Studio e la Prevenzione OncologicaFlorenceItaly
  2. 2.International Agency for Research on CancerLyon cedex 08France
  3. 3.the Cancer Control CenterSan CristobalVenezuela

Personalised recommendations